https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21794 9 months or TTBF > 3 years. Conclusion: TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.]]> Wed 11 Apr 2018 15:10:15 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7041 Sat 24 Mar 2018 08:37:55 AEDT ]]> Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18127 Sat 24 Mar 2018 08:04:29 AEDT ]]> FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21357 Sat 24 Mar 2018 07:51:27 AEDT ]]> Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5594 Sat 24 Mar 2018 07:49:21 AEDT ]]> FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part II post-radical prostatectomy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28752 Sat 24 Mar 2018 07:37:36 AEDT ]]> Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41992 Mon 10 Jul 2023 11:24:21 AEST ]]>